" /> Dihydropyrimidine dehydrogenase deficiency - CISMeF





Preferred Label : Dihydropyrimidine dehydrogenase deficiency;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Dpd deficiency; Dpyd deficiency; Thymine-uraciluria, hereditary; Pyrimidinemia, familial;

Included titles and symbols : 5-fluorouracil toxicity;

Description : Dihyropyrimidine dehydrogenase deficiency shows large phenotypic variability, ranging from no symptoms to a convulsive disorder with motor and mental retardation in homozygous patients. In addition, homozygous and heterozygous mutation carriers can develop severe toxicity after the administration of the antineoplastic drug 5-fluorouracil (5FU), which is also catabolized by the DPYD enzyme. This is an example of a pharmacogenetic disorder (Van Kuilenburg et al., 1999). Since there is no correlation between genotype and phenotype in DPD deficiency, it appears that the deficiency is a necessary, but not sufficient, prerequisite for the development of clinical abnormalities (Van Kuilenburg et al., 1999; Enns et al., 2004).;

Inheritance : Autosomal recessive;

Molecular basis : Caused by mutation in the dihydropyrimidine dehydrogenase gene (DPYD, 612779.0001).;

Laboratory abnormalities : Increased urinary uracil; Increased urinary thymine; Decreased or absent dihydropyrimidine dehydrogenase activity;

Prefixed ID : #274270;

Details


You can consult :


Nous contacter.
09/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.